(Q47830109)

6 February 2018

title

Secretin for refractory schizophrenia. (English)

1 reference

6 February 2018

1 reference

7

Jeffrey A Lieberman

1 reference

6 February 2018

author name string

Brian B Sheitman

1

1 reference

6 February 2018

Michael B Knable

2

1 reference

6 February 2018

L Fredrik Jarskog

3

1 reference

6 February 2018

Miranda Chakos

4

1 reference

6 February 2018

Leslie H Boyce

5

1 reference

6 February 2018

John Early

6

1 reference

6 February 2018

language of work or name

English

0 references

publication date

1 February 2004

1 reference

6 February 2018

published in

Schizophrenia Research

1 reference

6 February 2018

volume

66

1 reference

6 February 2018

issue

2-3

1 reference

6 February 2018

page(s)

177-181

1 reference

6 February 2018

Abnormal cholecystokinin mRNA levels in entorhinal cortex of schizophrenics

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900068-9

7 January 2021

A randomized, double-blind, placebo-controlled trial of single-dose intravenous secretin as treatment for children with autism

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900068-9

7 January 2021

The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900068-9

7 January 2021

Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900068-9

7 January 2021

[3H]Neurotensin receptor densities in human postmortem brain tissue obtained from normal and schizophrenic persons. An autoradiographic study.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900068-9

7 January 2021

Effects of intravenous secretin on language and behavior of children with autism and gastrointestinal symptoms: a single-blinded, open-label pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900068-9

7 January 2021

Antipsychotic effects of ceruletide (caerulein) on chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900068-9

7 January 2021

Multisite, double-blind, placebo-controlled trial of porcine secretin in autism

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900068-9

7 January 2021

Repeated doses of porcine secretin in the treatment of autism: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900068-9

7 January 2021

Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900068-9

7 January 2021

Narcolepsy: a key role for hypocretins (orexins)

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900068-9

7 January 2021

Increased tachykinin NK(1) receptor immunoreactivity in the prefrontal cortex in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900068-9

7 January 2021

Cholecystokinin CCK(B) receptor mRNA isoforms: expression in schizophrenic brains

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900068-9

7 January 2021

10.1016/S0920-9964(03)00068-9

Identifiers

DOI

1 reference

6 February 2018

PubMed ID

15061251

1 reference

6 February 2018